Noble Capital Markets Initiates Coverage On MAIA Biotechnology With Outperform Rating, Announces Price Target of $14
Noble Capital Markets Initiates Coverage On MAIA Biotechnology With Outperform Rating, Announces Price Target of $14
Noble Capital Markets以跑赢大盘的评级开始对MAIA生物技术进行报道，宣布目标股价为14美元
Noble Capital Markets analyst Robert LeBoyer initiates coverage on MAIA Biotechnology (AMEX:MAIA) with a Outperform rating and announces Price Target of $14.
Noble Capital Markets分析师罗伯特·勒博耶以跑赢大盘的评级开始对MAIA生物技术（AMEX: MAIA）进行报道，并宣布目标股价为14美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。